A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This study was an early-phase trial arranged into two phases. The Phase I portion was a
dose-escalation study designed to assess the safety, tolerability and to identify the maximum
tolerated dose of SB-743921 in patients with Non-Hodgkin Lymphoma and Hodgkin Lymphoma. Phase
II was intended to assess the activity, safety and tolerability of SB-743921 in patients with
Indolent and Aggressive Non-Hodgkin's Lymphomas exclusively. The Phase II portion of the
study was not initiated.